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Figure 2: [HA] in OA SF over time during treatment with IA HA or corti-
costeroid. Each line represents 1 knee, and circular markers denote knee
SF from the left (ﬁlled circles) and right (open circles) knee of 1 patient. SF
was aspirated prior to therapeutic injection. Black markers denote an IA
corticostreoid injection was received after aspiration. Red markers denote
an IA HA injection was received after aspiration. Grey shaded area shows
average [HA] in normal SF  95% CI.
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TEMPORAL EFFECTS OF INTRA-ARTICULAR HA AND/OR
CORTICOSTEROIDS ON OA SYNOVIAL FLUID BOUNDARY LUBRICANT
COMPOSITION: A CASE SERIES
T. Ludwig, J. McAllister, V. Lun, P. Wiley, T. Schmidt. Univ. of Calgary,
Calgary, AB, Canada
Purpose: Proteoglycan 4 (PRG4) and hyaluronan (HA) are critical
boundary lubricants present in synovial ﬂuid (SF) and at the surface of
articular cartilage. Deﬁciency of PRG4 or HA concentration and/or
molecular weight (MW) in SF may lead to compromised boundary
lubrication, which can be restored in vitro by lubricant supplementa-
tion. Intra-articular (IA) corticosteroids (CST) can provide short-term
pain relief for patients with osteoarthritis (OA), and IA HA can provide
pain relief for up to 6 months despite its comparatively short residence
time in the joint (hours to days). While IA CST can decrease local
inﬂammation and IA HAmay stimulate endogenous HA production, the
effects of IA treatment on SF boundary lubricant composition over time
remain unclear. The purpose of this study was to measure PRG4 and HA
content in SF aspirated from the same OA patient knee joint over time
during the course of treatment with IA CST and/or HA.
Methods: In an ongoing study, knee SF was aspirated from chronic OA
patients prior to IA treatment. Patients were included in this case series
if 3 or more SF aspirations were available for analysis. SF was stored at
-80C with protease inhibitors (PI’s) until use, and without PI’s for HA
MW analysis when enough volume was available. In total, 4 knees (3
patients) with 3-5 aspirations were available for analysis (age 49-54,
aspirated SF volume range 2-60 mL). Two patients (3 knees) had 1 HA
and 2 CST injections over 6-9 months, and 1 patient had 1 HA and 4 CST
injections over 34 months. IA HA received was hylan G-F 20, CST
received was Depo-Medrol. PRG4 and HA concentration was measured
by sandwich enzyme linked immunosorbent assay. HA MW was
measured by 1% agarose gel electrophoresis. SF boundary lubricant
composition data from 29 normal cadaveric SF samples are included for
comparison (average value95% conﬁdence interval (CI)).
Results: No consistent trends in SF lubricant composition after IA HA or
CST treatment were observed over time. PRG4 concentration in 3 of the
4 knees appeared to be lower than the normal range. PRG4 concen-
tration increased in 1 knee over time with IA CST, decreased in 1 knee
with IA HA and CST, and ﬂuctuated over time in 2 knees with IA HA and
CST (Fig. 1). HA concentration in 2 knees appeared to be higher than the
normal range; HA concentration decreased over time in 1 knee with IAFigure 1: [PRG4] in OA SF over time during treatment with IA HA or
corticosteroid. Each line represents 1 knee, and circular markers denote
knee SF from the left (ﬁlled circles) and right (open circles) knee of 1
patient. SF was aspirated prior to therapeutic injection. Black markers
denote an IA corticostreoid injection was received after aspiration. Red
markers denote an IA HA injection was received after aspiration. Grey
shaded area shows average [PRG4] in normal SF  95% CI.
Figure 3: HA MW distribution (high MW 3 - 6 MDa and low MW< 0.5
MDa) in OA SF over time during treatment with IA HA or corticosteroid.
Each line represents 1 knee, and circular markers denote knee SF from the
left (ﬁlled circles) and right (open circles) knee of 1 patient. SF was as-
pirated prior to therapeutic injection. Black markers denote an IA cortico-
streoid injection was received after aspiration. Red markers denote an IA
HA injection was received after aspiration. Grey shaded area shows
average HA MW in normal SF  95% CI.CST, and ﬂuctuated in 3 knees with IA HA and CST (Fig. 2). Three of 4
knees appeared to have lower than normal high MW (3-6 MDa) HA
content. HighMWHA ﬂuctuated over time in 1 kneewith IA HA and CST
and 1 knee with IA CST, decreased over time in 1 knee with IA CST and
remained stable over time in 1 knee with IA HA and CST (Fig. 3, top).
Three of 4 knees appeared to have higher than normal low MW (<0.5
MDa) HA content. Low MW HA ﬂuctuated over time in 1 knee with IA
HA and CST and 1 knee with IA CST, remained stable over time in 1 knee
with IA HA and CSTand increased over time in 1 kneewith IA CST (Fig. 3,
bottom).
Conclusions: IA HA did not appear to result in an increased abundance
of high MW HA in these patients, nor in consistent changes in HA or
PRG4 content. The times between aspirations in this study were above
the predicted times for PRG4 and HA to reach steady-state following
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response to IA treatments. Other factors including joint loading, activity
level, and inﬂammation may also inﬂuence SF lubricant composition
over time. As such, the present study suggests that boundary lubricant
composition of SF in OA joints can change over time with repeated IA
treatment, and that this response to IA CST or HA treatment appears to
vary between individuals. IA PRG4 has been shown to stimulate
endogenous production of PRG4 in preclinical models, and PRG4 can
affect boundary lubricating and rheological properties of HAþPRG4
solutions and SF in vitro. Furthermore, PRG4 concentrations appear to
be decreased in some chronic OA patients, suggesting that future study
of IA PRG4HA is warranted and could provide further insight into the
mechanism of action of IA HA(PRG4) biotherapeutic treatments. The
outcome of such future analysis of SF lubricant composition, boundary
lubricating function, and pain relief provided by IA PRG4HA might
ultimately be beneﬁcial for chronic, symptomatic OA patients with
compromised SF boundary lubricant composition.
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FULL-THICKNESS CARTILAGE DEFECTS REPAIR WITH
MICROFRACTURE TECHNIQUE AND INTRA-ARTICULAR INJECTION
OF A SMALL MOLECULE COMPOUND KARTOGENIN
X. Xu, Y. Shen, D. Shi, Q. Jiang. Sports Med. and Adult Reconstruction,
Nanjing, China
Purpose: To evaluate the outcome of . Methods: Full-thickness cartilage
defects were created in patellar groove of both femurs in 24 female New
Zealand White rabbits. The defects were then performed microfracture
surgery. The animals were divided into two groups according to post-
operative treatment. 12 rabbits were treated with intra-articular
injection of kartogenin (KGN) for once a week (Group A); the other 12
rabbits were treated with intra-articular injection of DMSO for once a
week (Group B). Animals were scariﬁced at 1 and 3months after
injection. 6 rabbits from each group at every time interval were killed
and the knees were harvested. The defects repair was assessed byMacroscopic, hematoxylin and eosin staining, toluidine blue staining,
and immunohistochemical stain for collagen type II. Differences
between groups at each time point were analyzed.
Results: 1month after treatment, no signiﬁcant differencewas detected
between Group A and Group B. After 3 months’ weekly injection, Group
A showed signiﬁcantly better macroscopic view, quality of repair tissue
and lateral integration than Group B.
Conclusions: 3 months’ intra-articular injection of KGN after
microfracture signiﬁcantly improve the effectiveness of treatment
full-thickness cartilage defects in comparition with isolated micro-
fractures.
Therapy: Biological
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THE S100A9 INHIBITOR PAQUINIMOD (ABR-215757) REDUCES
SYNOVIAL ACTIVATION, OSTEOPHYTE FORMATION AND CARTILAGE
DAMAGE IN EXPERIMENTAL OSTEOARTHRITIS
R.F. Schelbergen y, A.B. Blom y, T. Leanderson z, H. Eriksson x,
W.B. van den Berg y, P.M. van der Kraan y, P.L. van Lent y. yRadboud Univ.
Med. center, Nijmegen, Netherlands; z Lund Univ., Lund, Sweden; xActive
Biotech AB, Lund, Sweden
Purpose: Synovial activation is present in a large subset of osteo-
arthritis (OA) patients and it is thought to play an important role in the
development of OA pathology. Previously, we found that activated
macrophage products S100A8 and S100A9 are involved in cartilage
degradation and synovial activation during experimental OA. Paquini-
mod is a quinoline-3-carboxamide compound with immunomodula-
tory properties that is currently in clinical development for treatment of
systemic sclerosis. It targets the S100A9 protein and blocks the binding
of S100A9 to RAGE and TLR-4.In the current study we investigated the
effect of the S100A9-blocking compound paquinimod on experimental
osteoarthritis with different degrees of synovial activation.
Methods: Collagenase induced OA (CIOA) was induced by two times
intra-articular injection of 1U collagenase and DMM was induced by
transsection of the medial anterior meniscotibial ligament leading to
destabilization of the medial meniscus (DMM), both in C57Bl6 mice.
Paquinimod (3,75 mg/kg) was administered in the drinking water 4
days before induction of OA in both CIOA and DMM and refreshed
twice a week. Whole knee joints were isolated and embedded in
parafﬁn for histological sectioning. Synovial thickening and cellu-
larity was measured using an arbitrary score from 0-3. OA-like car-
tilage pathology was scored using a modiﬁed Pritzker OARSI score.
Osteophyte size was measured by a blinded observer using image
analysis software.
Results: First, we assessed the effect of paquinimod on DMM devel-
opment on day 56. Synovial activation in this surgical model is low, as
are S100A8/A9 levels in the synovium. No differences were observed on
osteophyte size between paquinimod-treated and non-treated animals
at both medial tibia and medial femur. Furthermore, OA-like cartilage
pathology was only signiﬁcantly reduced by paquinimod-treatment at
